Lombard Odier Asset Management USA Corp Has $45.71 Million Position in Silence Therapeutics plc (NASDAQ:SLN)

Lombard Odier Asset Management USA Corp increased its position in Silence Therapeutics plc (NASDAQ:SLN) by 0.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,405,998 shares of the company’s stock after buying an additional 17,086 shares during the quarter. Silence Therapeutics accounts for 3.4% of Lombard Odier Asset Management USA Corp’s portfolio, making the stock its largest position. Lombard Odier Asset Management USA Corp owned about 8.04% of Silence Therapeutics worth $45,714,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. SG Americas Securities LLC lifted its position in Silence Therapeutics by 10.5% in the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock valued at $151,000 after purchasing an additional 667 shares during the last quarter. Custom Index Systems LLC bought a new stake in Silence Therapeutics in the second quarter valued at approximately $282,000. Legato Capital Management LLC bought a new stake in Silence Therapeutics in the second quarter valued at approximately $376,000. Nicholas Investment Partners LP bought a new stake in Silence Therapeutics in the second quarter valued at approximately $2,859,000. Finally, Parkman Healthcare Partners LLC lifted its position in Silence Therapeutics by 20.8% in the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,063 shares during the last quarter. Institutional investors own 98.73% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on SLN. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, August 30th. Morgan Stanley boosted their target price on Silence Therapeutics from $45.00 to $49.00 and gave the company an “overweight” rating in a research note on Friday, June 28th. Chardan Capital reissued a “buy” rating and set a $55.00 target price on shares of Silence Therapeutics in a research note on Friday, August 16th. Finally, Jefferies Financial Group began coverage on Silence Therapeutics in a research note on Tuesday, September 3rd. They set a “buy” rating and a $40.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $57.20.

Silence Therapeutics Stock Down 0.2 %

Shares of SLN stock opened at $18.27 on Monday. The stock has a market cap of $546.78 million, a price-to-earnings ratio of -15.75 and a beta of 1.29. The business’s fifty day moving average is $18.57 and its 200 day moving average is $20.40. Silence Therapeutics plc has a twelve month low of $6.15 and a twelve month high of $27.72.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.10). The firm had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $11.28 million. Silence Therapeutics had a negative return on equity of 58.28% and a negative net margin of 222.44%. Equities research analysts expect that Silence Therapeutics plc will post -1.55 earnings per share for the current fiscal year.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.